Search Results
197 items found for "POTS"
- Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
path forward for dipraglurant in a number of interesting disease areas in parallel to discussions with potential
- RAB-Symposium - Regulatory Autoantibodies Targeting GPCRs. September 15-16, 2022. Lübeck, Germany...
autoantibodies targeting GPCRs have been associated with various disease-specific manifestations, highlighting a potential
- Discovery of 3(2-aminoethyl)-thiazolidine-2,4-diones as a novel chemotype of sigma-1 receptor ligand
Therefore, S1R ligands possess a variety of potential clinical applications with a great interest in Upon optimization, this series of compounds could represent potential clinically useful S1R ligands for
- Actions of Parathyroid Hormone Ligand Analogues in Humanized PTH1R Knockin Mice
(PTH) and PTH-related protein (PTHrP) ligands and analogues for their pharmacologic activities and potential PTH1Rs are 91% identical to the human PTH1R) can lead to differences in receptor-binding and signaling potencies To overcome this potential uncertainty, we used a homologous recombination-based knockin (KI) approach The initial evaluation of these mice and their potential utility for predicting behavior of PTH analogues
- Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate ...
advance cancer immunotherapy candidate into clinical trials " HTL0039732 is a novel EP4 antagonist with potential
- Orion Shares New Data on its Latest Best-in-Class Drug Candidate
Orion Biotechnology Canada Ltd, a drug discovery and development company unlocking the therapeutic potential
- Accelerating GPCR Drug Discovery With Conformation-Stabilizing VHHs
GPCRome (consisting of approximately 850 GPCRs) has been successfully drugged, and obtaining highly potent
- Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR
access to the Sosei Heptares compound library for its industry-leading biology platform to identify potential
- Targeting the M1 muscarinic receptor in neurodegenerative disease
characterizing the role of the muscarinic M1 receptor in cognitive and neurodegenerative disorders and the potential
- Modulation of Striatal Adenosinergic Function by HTL0041178, a Selective GPR52 Agonist
highlights an important interplay between the adenosinergic and dopaminergic systems and suggests the potential
- Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment ...
Allosteric Modulator Program For The Treatment Of Schizophrenia & Other Psychotic Disorders " New Series of Potent modulation-based drug discovery and development, announced today that it has moved a selective and potent M4 PAMs have the potential to treat schizophrenia and other types of debilitating neuropsychiatric disorders
- Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical ...
that patient enrollment has been completed in its Phase 2a clinical study evaluating dipraglurant as a potential
- Self-docking and cross-docking simulations of G protein-coupled receptor-ligand complexes
tools and drug leads is aided by molecular docking simulations that allow critical analysis of the potential
- Recurrent high-impact mutations at cognate structural positions in class A G protein-coupled ...
mutations located at cognate positions across GPCR paralogs opens a window into cancer mechanisms and potential
- HBx induces hepatocellular carcinogenesis through ARRB1-mediated autophagy to drive the G 1/S cycle
HBV-related HCC via modulating autophagy and the CDKN1B-CDK2-CCNE1-E2F1 axis and indicate that ARRB1 may be a potential
- GPCR voltage dependence controls neuronal plasticity and behavior
Almost 20 years ago, GPCR activity was shown to be regulated by membrane potential in vitro, but whether Here we show that muscarinic GPCR mediated neuronal potentiation in vivo is voltage dependent. This voltage dependent potentiation is abolished in mutant animals expressing a voltage independent receptor Depolarization alone, without a muscarinic agonist, results in a nicotinic ionotropic receptor potentiation
- Opioid Receptors and Protonation-Coupled Binding of Opioid Drugs
The potentially low pH at tissue targeted by opioid drugs in pain management could impact drug binding
- Chemogenetic stimulation of the G i pathway in astrocytes suppresses neuroinflammation
astrocytic Gi pathway plays an inhibitory role in neuroinflammation, providing an opportunity to identify potential
- G protein-coupled receptor interactions and modification of signalling involving the ghrelin ...
receptor, GHSR1a The growth hormone secretagogue receptor 1a (GHSR1a) is intriguing because of its potential Initial studies of the receptor focused on the potential therapeutic ability for growth hormone (GH)
- In Vitro and In Silico Characterization of Kurarinone as a Dopamine D 1A Receptor Antagonist and ...
With appreciable D2LR and D4R agonism and D1R antagonism, kurarinone might be a potential compound that
- In vivo metabolic effects after acute activation of skeletal muscle G s signaling
The acute metabolic effects following agonist activation of β2-adrenergic and, potentially, CRF2 receptors
- Chemical signaling regulates axon regeneration via the GPCR-Gqα pathway in Caenorhabditis elegans
injury is determined by the interaction between the extracellular environment and intrinsic growth potential
- G protein-coupled receptor kinase 2 is essential to enable vasoconstrictor-mediated arterial ...
Considering VSMC GRK2 expression increases early in the development of hypertension, this highlights the potential
- The development of modulators for lysophosphatidic acid receptors: A comprehensive review
status of ligand development targeting LPA receptors to modulate LPA signaling and their therapeutic potential
- TLR4 biased small molecule modulators
Biased pharmacological modulators provide potential therapeutic benefits, including greater pharmacodynamic
- Disentangling bias between G q, GRK2, and arrestin3 recruitment to the M 3 muscarinic acetylcholine
Different agonists can promote differential receptor-induced signaling responses - termed bias - potentially
- First in Human: Early-stage COVID therapies hold promise against omicron variant
studies of COVID-19 treatments from the likes of Vir Biotechnology Inc. and Trevena Inc. could offer potential
- Orion Announces The Rapid Lead Optimization Of Ob-004 - A Ccr2 Antagonist
, Canada, Nov. 30, 2021 -- Orion Biotechnology , a clinical stage company unlocking the therapeutic potential